Lineage Cell Therapeutics Q3 revenue up 34% YoY to $5.6 mln.
ByAinvest
Thursday, Nov 6, 2025 4:19 pm ET1min read
LCTX--
• Lineage Cell Therapeutics reports Q3 2025 financial results • Positive RG6501 (OpRegen) Phase 1/2a clinical study 36-month results featured • Entered collaboration with William Demant Invest to develop ReSonance for hearing loss • Initiated manufacturing scale project in type 1 diabetes cell therapy • Conference call scheduled for 4:30 p.m. Eastern Time
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet